The flexible design of the PFSI™ adapts to the unique needs of each therapy, ensuring formulation compatibility and optimal patient outcomes.
Spray and aerosol profiles can be optimised for specific formulations, while customisable metered dosing enables precise, targeted treatment. Sensitive molecules are safeguarded through gentle, low-shear delivery that preserves their integrity.
Available in both reusable and disposable formats, the PFSI™ adaps to different treatment schedules ranging from single-day courses to month-long regimens. With intuitive flow guidance and ergonomic design, drug delivery and lung deposition are optimised for each patient group, making every therapy not only effective, but also safe and convenient.
The PFSI™ is built on a platform designed for smooth translation from early-stage development to large-scale commercial production.
Its modular design enables rapid adaptation to different therapies without compromising quality or performance. Scalable processes, compatible with existing pharmaceutical infrastructure, ensure efficient manufacturing at every stage—from clinical batches to global supply.
Robust primary glass packaging maintains stability and sterility, while precision engineering guarantees consistent spray performance across every unit. With a future-ready production framework, the PFSI™ offers partners confidence in seamless upscaling, regulatory alignment, and reliable market delivery.
Gentle aerosolisation for mRNA, proteins, and complex modalities
The PFSI™ Soft Mist Inhaler is designed to protect fragile biologics and small molecules during pulmonary delivery. Leveraging low-shear Rayleigh nozzle technology and high-quality glass primary packaging, the system preserves molecular integrity throughout aerosolisation, making it ideally suited for mRNA-, protein-, and other complex therapeutic modalities.
